Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB
29/09/2026 12:30
BRIEF-Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB Sept 29 (Reuters) - Cognition Therapeutics Inc CGTX.O:
COGNITION THERAPEUTICS SCHEDULES A TYPE C MEETING WITH FDA TO ALIGN ON ENDPOINTS FOR PHASE 3 TRIAL OF ZERVIMESINE (CT1812) IN DLB
COGNITION THERAPEUTICS - MEETING TO ALIGN ON PRIMARY ENDPOINT FOR ZERVIMESINE PHASE 3 DLB STUDY
COGNITION THERAPEUTICS - SCHEDULES TYPE C FDA MEETING FOR OCTOBER 20, 2026
Source text: ID:nGNX3Zdvdz
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB